Modelling the impact of migrants on the success of the HIV care and treatment program in Botswana.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 02 09 2019
accepted: 26 11 2019
entrez: 16 1 2020
pubmed: 16 1 2020
medline: 9 4 2020
Statut: epublish

Résumé

Botswana offers publicly financed HIV treatment to citizens, but not migrants, who comprised about 7% of the population in 2016. However, HIV incidence is not declining in proportion to Botswana's HIV response. In 2018, Botswana had 86% of citizens living with HIV diagnosed, 95% of people diagnosed on treatment, and 95% viral suppression among those on treatment. We hypothesised that continued exclusion of migrants is hampering reduction of HIV incidence in Botswana. Hence, we modelled the impact of including migrants in Botswana's HIV response on achieving 90-90-90 and 95-95-95 Fast-Track targets by 2020 and 2030, respectively. The Optima HIV model, with demographic, epidemiological, and behavioural inputs, was applied to citizens of and migrants to Botswana. Projections of new HIV infections and HIV-related deaths were compared for three scenarios to the end of 2030: (1) continued status quo for HIV testing and treatment coverage, and maintenance of levels of linkage to care, loss to follow-up, and viral suppression among citizens and migrants (baseline); (2) with scaled-up budget, optimised to achieve 90-90-90 and 95-95-95 Fast-Track targets by 2020 and 2030, respectively, for citizens only; and (3) scaled-up optimised budget to achieve these targets for both citizens and migrants. A baseline of 172,000 new HIV infections and 8,400 HIV-related deaths was projected over 2020-2030. Scaling up to achieve targets among citizens only averted an estimated 48,000 infections and 1,700 deaths. Achieving targets for both citizens and migrants averted 16,000 (34%) more infections and 442 (26%) more deaths. Scaling up for both populations reduced numbers of new HIV infections and deaths by 44% and 39% respectively compared with 2010 levels. Treating migrants when scaling up in both populations was estimated to cost USD 74 million over 2020-2030. Providing HIV services to migrants in Botswana could lead to further reductions in HIV incidence and deaths. However, even with an increased, optimised budget that achieves 95-95-95 targets for both citizens and migrants by 2030, the 90% incidence reduction target for 2020 will be missed. Further efficiencies and innovations will be needed to meet HIV targets in Botswana.

Identifiants

pubmed: 31940360
doi: 10.1371/journal.pone.0226422
pii: PONE-D-19-24757
pmc: PMC6961860
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0226422

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2018 Oct 24;13(10):e0204840
pubmed: 30356287
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25137
pubmed: 30027621
Lancet Public Health. 2017 May;2(5):e223-e230
pubmed: 29253488
SAHARA J. 2014;11:158-66
pubmed: 25293869
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
BMJ Open. 2016 Jul 07;6(7):e011914
pubmed: 27388363
AIDS. 2016 Jan 28;30(3):477-85
pubmed: 26636931
Eur J Public Health. 2018 Oct 1;28(5):904-910
pubmed: 29982518
Int Health. 2015 Mar;7(2):107-13
pubmed: 25733560
AIDS. 2006 Sep 11;20(14):1898-901
pubmed: 16954735
J Int AIDS Soc. 2018 Mar;21(3):
pubmed: 29508945
AIDS. 2017 Sep 10;31(14):1979-1988
pubmed: 28857779
PLoS Med. 2018 Oct 25;15(10):e1002678
pubmed: 30359372
Medicine (Baltimore). 2019 Jun;98(23):e15994
pubmed: 31169739
BMC Public Health. 2015 Jun 19;15:561
pubmed: 26085030
BMC Infect Dis. 2014 Jun 24;14:350
pubmed: 24961725
Lancet HIV. 2016 Sep;3(9):e409
pubmed: 27562741
Clin Infect Dis. 2018 Mar 19;66(7):1019-1023
pubmed: 29099920
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):257-63
pubmed: 25886932
Int J Infect Dis. 2019 Jan;78:57-64
pubmed: 30391417
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):365-76
pubmed: 25803164
Lancet HIV. 2018 Apr;5(4):e181-e189
pubmed: 29490875
Lancet HIV. 2018 Apr;5(4):e190-e198
pubmed: 29540265

Auteurs

Tafireyi Marukutira (T)

Burnet Institute, Melbourne, Australia.
Monash University, Melbourne, Australia.

Nick Scott (N)

Burnet Institute, Melbourne, Australia.

Sherrie L Kelly (SL)

Burnet Institute, Melbourne, Australia.

Charles Birungi (C)

UNAIDS, Gaborone, Botswana.
University College London, London, England, United Kingdom.

Joseph M Makhema (JM)

Botswana Harvard Partnership, Gaborone, Botswana.

Suzanne Crowe (S)

Burnet Institute, Melbourne, Australia.
Monash University, Melbourne, Australia.

Mark Stoove (M)

Burnet Institute, Melbourne, Australia.
Monash University, Melbourne, Australia.

Margaret Hellard (M)

Burnet Institute, Melbourne, Australia.
Monash University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH